10 December 2021 in Nature Aging
30 May 2024 in Nature Aging
It has been reported that accumulation of senescent cells in various tissues contributes to pathological aging and that elimination of senescent cells (senolysis) improves age-associated pathologies. Here, we demonstrate that inhibition of sodium–glucose co-transporter 2 (SGLT2) enhances clearance of senescent cells, thereby ameliorating age-associated phenotypic changes. In a mouse model of dietary obesity, short-term treatment with the SGLT2 inhibitor canagliflozin reduced the senescence load in visceral adipose tissue and improved adipose tissue inflammation and metabolic dysfunction, but normalization of plasma glucose by insulin treatment had no effect on senescent cells. Canagliflozin extended the lifespan of mice with premature aging even when treatment was started in middle age. Metabolomic analyses revealed that short-term treatment with canagliflozin upregulated 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside, enhancing immune-mediated clearance of senescent cells by downregulating expression of programmed cell death-ligand 1. These findings suggest that inhibition of SGLT2 has an indirect senolytic effect by enhancing endogenous immunosurveillance of senescent cells.
27 March 2026 in Circulation Research
BACKGROUND: Pulmonary hypertension (PH) is characterized by increased pulmonary artery pressure and can lead to right heart failure. Parathyroid hormone (PTH) is secreted by the parathyroid gland and plays a crucial role in calcium homeostasis. PTH also acts on the cardiovascular system and affects cardiovascular prognosis. We hypothesized that PTH would play a potential role in the pathogenesis of PH. METHODS: Serum PTH levels were measured in patients with PH or suspected PH who underwent evaluation using right heart catheterization. We assessed whether the regulation of PTH and the PTH1R (PTH receptor) affected PH in a hypoxia-induced PH mouse model and a Sugen/hypoxia-induced PH rat model. To examine PTH1R regulation and the direct effects of PTH, human pulmonary artery smooth muscle cells were cultured. RESULTS: In the clinical study, we found that serum PTH concentration was associated with both mean pulmonary artery pressure and pulmonary vascular resistance, with a cutoff PTH level of 46.0 pg/mL (68.2% sensitivity, 100% specificity) for predicting PH. In the PH animal models—Sugen/hypoxia rats and hypoxia mice—PTH treatment exacerbated right ventricular hypertrophy and right ventricular systolic pressure. Conversely, PTH reduction by parathyroidectomy attenuated right ventricular hypertrophy and reduced pulmonary vascular remodeling in Sugen/hypoxia rats. In vitro studies revealed that HIF1α (hypoxia-inducible factor-1 alpha) promoted the PTH1R. Moreover, knockdown of the PTH receptor in the lungs ameliorated PH in Sugen/hypoxia rats and hypoxia mice. Treatment with PTH increased proliferation and migration of pulmonary artery smooth muscle cells through the PTH receptor–β-arrestin–ERK (extracellular signal-regulated kinase) signaling axis. CONCLUSIONS: Our clinical and experimental data suggest a potential involvement of PTH/PTH1R signaling in the development and progression of PH, highlighting PTH1R as a possible therapeutic target for further investigation.
1 August 2017 in European Heart Journal
Background: Accumulation of senescent vascular endothelial cells impair the vessel homeostasis, however, underlying mechanisms are largely unknown. We identified a novel protein, senescence-associated glycoprotein (SAGP), as a biomarker of endothelial cell senescence and found that SAGP is critically involved in promoting angiogenesis.